Devang Bhoiwala, MD
Ophthalmology · Bloomfield, NJNPI 1043674229
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 184 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Alcon at 28.7% of the total. 2025 is the largest year on record at $4,603, more than ten times the $408 reported in 2021. Among ophthalmology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 184 payments — averaging $67.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$4K
- Glaukos Corporation$3K
- AbbVie$2K
- Sight Sciences, Inc.$1K
- Bausch & Lomb Americas Inc.$743
- Tarsus Pharmaceuticals, Inc.$622
- plus $627 from 11 others
What the payments were for
- Food & beverage$12,362100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 34 | $3,546 |
| Glaukos Corporation | 27 | $3,300 |
| AbbVie(2 entities) | 53 | $2,405 |
| Sight Sciences, Inc. | 14 | $1,120 |
| Bausch & Lomb Americas Inc. | 26 | $743 |
| Tarsus Pharmaceuticals, Inc. | 15 | $622 |
| Sun Pharmaceutical Industries Inc. | 2 | $124 |
| Aerie Pharmaceuticals, Inc. | 1 | $118 |
| Nova Eye, Inc. | 1 | $93 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $62 |
| Thea Pharma Inc. | 3 | $54 |
| Sanofi | 1 | $49 |
| Rxsight Inc | 1 | $40 |
| Halozyme Inc | 1 | $28 |
| Rayner Intraocular Lenses Limited | 1 | $23 |
| Harrow Eye, LLC | 1 | $18 |
| Dompe US, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$1,817
- XEN GLAUCOMA TREATMENT SYSTEM$1,577
- OMNI(R) SURGICAL SYSTEM (US)$822
- iDose$796
- iDoseTR$792
- SION SURGICAL INSTRUMENT$686
- IACCESS$540
- iStent inject W$540
- Clareon$527
- XDEMVY$481
- iS3-iStent infiniteTrabecular Micro-Bypass System Model iS3$293
- DURYSTA$257
- MIEBO$241
- enVista MX60 IOL$227
- iStent Trabecular Micro-Bypass System Model iS3$187
- iStent$178
- iStent Infinite$148
- Clareon PanOptix Pro$146
- XIIDRA$125
- AcrySof IQ PanOptix UV IOL$121
How this compares
$12,362 in reported general payments places this provider in the 90th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 18 | $31,558 |
| RocklatanNetarsudil Mesylat/Latanoprost | 46 | $29,219 |
| LumiganBimatoprost | 43 | $18,081 |
| RestasisCyclosporine | 15 | $14,619 |
| RhopressaNetarsudil Mesylate | 14 | $9,799 |
| Prednisolone Acetate | 227 | $8,618 |
| Alphagan PBrimonidine Tartrate | 22 | $8,055 |
| Brimonidine Tartrate | 61 | $7,883 |
| VyzultaLatanoprostene Bunod | 18 | $7,462 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 32 | $4,288 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 16 | $3,242 |
| Travoprost | 11 | $3,183 |
| Ketorolac Tromethamine | 133 | $2,364 |
| Latanoprost | 170 | $2,304 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 79 | $1,264 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P | $2,405 | $40,75580 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $743 | $39,02036 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $118 | $39,01860 claims |
| AlconSimbrinza | $3,546 | $3,24216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Bloomfield
- Lauren AngiolettiBloomfield$8K
- Jai ParekhWoodland Park$2M
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Cynthia MatossianPennington$655K
- Eric MannDover$604K
- Brett BieloryRutherford$477K
- Albert KhouriNewark$428K
- Robert FechtnerNewark$324K
- Rajen DesaiFreehold$311K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.